A follow-up study of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients

Trial Profile

A follow-up study of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2017 Results from a subset of initially randomized 36 patients (n = 19) presented in an ASIT Biotech media release.
    • 24 Oct 2017 According to an ASIT Biotech media release, this trial was performed at the Carl Gustav Carus University Hospital in Dresden, Germany.
    • 24 Oct 2017 Status changed from planning to active, no longer recruiting, according to an ASIT Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top